Corrigendum to "The 0.19-mg Fluocinolone Acetonide Intravitreal Implant Reduces Treatment Burden in Diabetic Macular Edema" [Am J Ophthalmol 2023;248;16-23].

The authors regret that in the April 2023 issue, recently discovered information affects the data points in one table and one associated sentence in the text. The changes do not alter the conclusions or impact of the publication. Discussion section, paragraph 5, line 11 should read as follows: Of the 8 cases requiring incisional IOP-lowering surgery, 3 cases were due to neovascular glaucoma: 1 case was among those who had no supplemental treatments after FAc, and 2 cases were among those who received supplemental treatments after FAc. Table 2 should read as follows with changes applied to column 2 row 7, column 3 rows 6 and 7, and column 4 row 7:Table 2Intraocular Pressure-Related Events After FAc Implant Administration, All eyes (n = 202).No Supplemental Treatments (n = 77) (Mean Follow-up of 21.6 mo)Received Supplemental TreatmentsaAnti-VEGF (76.5%); corticosteroid (8.4%); laser (7.8%) (n = 125) (Mean Follow-up of 31.2 mo)Received Supplemental Steroid Treatments (n = 42) (Mean Follow-up of 32.2 mo)IOP-Related EventPost-FAc Administration, % (n)Post-FAc Administration, % (n)Post-FAc Administration, % (n)IOP elevation to >25 mm Hg18.2 (14)27.2 (34)35.7 (15)IOP elevation to >30 mm Hg6.5 (6)13.6 (17)21.4 (9)Trabeculoplasty1.3 (1)2.4 (3)2.4 (1)Incisional IOP-lowering surgery2.6 (2)bOne case due to neovascular glaucoma.4.8 (6)cTwo cases due to neovascular glaucoma.0.0 (0)Any IOP-lowering medication19.5 (15)36.8 (46)40.5 (17)FAc = fluocinolone acetonide, IOP = intraocular pressure.a Anti-VEGF (76.5%); corticosteroid (8.4%); laser (7.8%)b One case due to neovascular glaucoma.c Two cases due to neovascular glaucoma. Open table in a new tab FAc = fluocinolone acetonide, IOP = intraocular pressure. The 0.19-mg Fluocinolone Acetonide Intravitreal Implant Reduces Treatment Burden in Diabetic Macular EdemaAmerican Journal of OphthalmologyVol. 248PreviewTo assess treatment burden in patients with diabetic macular edema (DME) after the 0.19-mg fluocinolone acetonide (FAc) intravitreal implant (ILUVIEN). Full-Text PDF Open Access